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Interleukin (IL)-6 is a cytokine featuring redundancy and pleiotropic activity. While IL-6, when transiently produced, contributes
to host defense against acute environmental stress, continuous dysregulated IL-6 production plays a signiﬁcant pathological role
in several systemic autoimmune diseases. In response to the expectation that IL-6 blockade would constitute a novel therapeutic
strategy for the treatment of these diseases, tocilizumab, a humanized anti-IL-6 receptor antibody, was developed. Clinical trials
haveveriﬁedtheeﬃcacyandthesafetyoftocilizumabforpatientswithrheumatoidarthritis,resultinginapprovalofthisinnovative
biologic for the treatment of rheumatoid arthritis in more than 90 countries worldwide. Pathological analyses of the eﬀe c to fI L -
6 on the development of autoimmune diseases and a considerable number of case reports and pilot studies have also indicated
the beneﬁcial eﬀects of this antibody on other systemic autoimmune diseases, including systemic lupus erythematosus, systemic
sclerosis, polymyositis, and large-vessel vasculitis.
1.Introduction
Interleukin (IL)-6 is a cytokine featuring redundancy and
pleiotropic activity. It was successfully cloned in 1996 as a
B-cell diﬀerentiation factor, which promotes B-cell diﬀeren-
tiationintoantibody-producingcells[1].Subsequentinvitro
studies and analysis of IL-6 transgenic mice have shown that
IL-6 acts not only on B cells but also on T cells, hepatocytes,
hematopoietic progenitor cells, and various other cells [2–4].
One of the important functions of IL-6 is the diﬀerentiation
of CD4positive na¨ ıve T cells into eﬀector cells. IL-6 in the
presence of TGF-β promotes na¨ ıve T-cell diﬀerentiation into
Th17 cells, while IL-6 inhibits TGF-β-induced regulatory T-
cell (Treg) diﬀerentiation [5], causing imbalance between
Th17 and Treg, which is a primary pathogenic factor in
several autoimmune diseases [6].
IL-6 transmits its signal through its binding to trans-
membrane receptors or the soluble IL-6 receptor (IL-6R)
[7,8].AfterbindingofIL-6toIL-6R,theresultantIL-6/IL-6R
complex associates with gp130 and induces homodimeriza-
tion of gp130, which triggers signal transduction system [9].
ThepathologicalsigniﬁcanceofIL-6fordiseaseswasﬁrst
demonstrated in a case of cardiac myxoma [10]. The culture
ﬂuid obtained from the myxoma tissues of a patient who
presented with fever, arthritis with positivity for antinuclear
factor, increased C-reactive protein (CRP) levels and hyper-
gammaglobulinemia and was diagnosed with undiﬀerenti-
ated connective tissue disease, contained a large quantity of
IL-6, which suggested that IL-6 might contribute pathologi-
cally to chronic inﬂammation and autoimmunity. Subseq-
uent studies have shown that dysregulation of IL-6 produc-
tion is implicated in the pathogenesis of Castleman’s disease
[11], rheumatoid arthritis (RA) [12], and various other
autoimmune, inﬂammatory, and malignant diseases [2–4].
Because of the biological activities of IL-6 and its
pathological role in diseases, it was anticipated that IL-6
blockage would constitute a novel treatment strategy for
autoimmune and inﬂammatory diseases [4, 13–15]. To this2 International Journal of Rheumatology
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Figure 1: Pathological role of IL-6 in rheumatoid arthritis. IL-6 is important for development of Th17 and induction of autoantibodies
such as rheumatoid factor. Activated Th17 cells and autoantibodies generate pannus in combination with activated ﬁbroblastic synoviocytes,
macrophages, and lymphocytes. Inﬂamed synovitis such as pannus is a major source of inﬂammatory cytokines including IL-6, and systemic
inﬂammation(resultinginproductionofacutephaseprotein,anemia,andfatigue)ismainlymediated byIL-6.Tumornecrosisfactor(TNF)
plays a major role in the progression of local types of inﬂammation (arthritis) such as arthralgia, swelling, and joint destruction but plays a
minor role during the priming phase.
end, tocilizumab was developed, which is a humanized anti-
IL-6R monoclonal antibody (Ab) of the IgG1 class that
was generated by grafting the complementarity determining
regions of a mouse anti-human IL-6R Ab onto human IgG1.
Tocilizumab blocks IL-6-mediated signal transduction by
inhibiting IL-6 binding to transmembrane and soluble IL-
6R.
2. Approval of Tocilizumab for the Treatment
of Rheumatoid Arthritis
2.1. Pathological Role of IL-6 in Rheumatoid Arthritis. RA is
a chronic, progressive inﬂammatory disease of the joints and
surrounding tissues accompanied by intense pain, irrever-
sible joint destruction, and systemic complications such as
fatigue, anemia, and fever [16]. At the local level, inﬂamma-
tory cells invade the otherwise relatively acellular synovium
leading to neovascularization, synoviocyte hyperplasia, and
formation of pannus tissue, which in turn causes destruction
ofcartilage,erosionoftheadjacentbone,and,ultimately,loss
of function of the aﬀected joint. The biological activities of
IL-6 such as proinﬂammatory activity, augmentation of syn-
ovial ﬁbroblast proliferation, osteoclast diﬀerentiation,
matrix metalloproteinase (MMP), and vascular endothelial
growth factor (VEGF) production, as well as lymphocyte
diﬀerentiation and its elevation in both serum and synovial
ﬂuids of patients with RA [17–22] indicate that IL-6 is one of
the key cytokines involved in the development of RA.
It has been demonstrated in animal model of RA, that
are type II collagen-induced arthritis (CIA), and antigen-in-
duced arthritis, IL-6 performs a major role in the develop-
ment and progression of joint destruction, while IL-6 def-
iciency generated by gene knockout or IL-6 blockade by
means of anti-IL-6R Ab reduces the incidence and severity of
arthritis in these models [23–28]. In the CIA model, immu-
nization with type II collagen predominantly increased the
frequency of Th17 cells and treatment of mice with anti-IL-
6R Ab during priming markedly suppressed the induction
of Th17 cells and arthritis development, while treatment
with anti-IL-6R Ab on day 14 failed to suppress both Th17
diﬀerentiation and arthritis [29]. Similarly, in a glucose-
6-phosphate-isomerase- (GPI-)induced arthritis model, ad-
ministration of anti-IL-6R Ab on day 0 or 3 suppressed Th17
diﬀerentiation and protected against arthritis induction,
while injection of anti-IL-6R Ab on day 14, at the peak of
arthritis, did not bring about any improvement in arthritis
[30]. Arthritis of anti-type II collagen antibody-induced ar-
thritis (CAIA) is another arthritis model, but, in this model,
the priming phase of T cell dependent antibody generation is
skipped. Although IL-6 is also elevated in this model, CAIA
w a sp r o f o u n d l ys u p p r e s s e di nT N F −/− mice but not in IL-
6−/− mice [31], indicating that TNF may play a more sig-
niﬁcant role in the development of CAIA than IL-6. These
observations suggest that in the priming phase IL-6 is a re-
quired factor for the activation of T cell response and pro-
duction of antibodies speciﬁc for joint components and that
in the eﬀector phase TNF is the main generator of arthritis
[32]. We found that tocilizumab was not eﬀective for clinical
improvement in the condition of two patients with psoriatic
arthritis, for whose development immune activation does
not appear to be required [33]. The clinical antiarthritic
eﬀect of tocilizumab is slower than that of TNF inhibitors,
which may be due to the diﬀerent pathological roles of IL-6
and TNF in the development of RA (Figure 1).
2.2. Eﬃcacy of Tocilizumab in Randomized Controlled Trials.
As shown in Table 1, seven phase III clinical trials of toci-
lizumab subsequent to phase I and II studies demonstrated
its eﬃcacy either as monotherapy or in combination with
disease-modifyingantirheumaticdrugs(DMARDs)foradultInternational Journal of Rheumatology 3
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Table 2:Reevaluationofantirheumaticeﬀectsoftocilizumabinactualmedicalpractice.Summaryofthecontentsofthethreeactualmedical
practice of tocilizumab for rheumatoid arthritis.
Study Country Patient number Registry Evaluation
TAMARA Germany 286 Sep. 2008∼Sep. 2009
Disease activity
EULAR response
ACR response
Adverse events
2011 ACR/EULAR remission
DAMBIO Denmark 178 ∼April 2010
Disease activity
EULAR response
Drug survival
REACTION Japan 229 April 2008∼March 2009
Disease activity
EULAR response
Adverse events
Drug survival
patients with moderate to severe RA [34–40]. A Cochrane
databasesystematicreviewconcludedthattocilizumab-treat-
edpatientstakingconcomitantmethotrexatewerefourtimes
more likely to achieve American College of Rheumatology
(ACR) 50 improvement (absolute %, 38.8% versus 9.6%)
and 11 times more likely to achieve Disease Activity Score
(DAS) remission (30.5% versus 2.7%) than patients taking a
placebo [41]. Furthermore, the SAMURAI [34] and LITHE
studies [40] proved that radiological damage of joints was
signiﬁcantly inhibited by the treatment. The ﬁndings of the
RADIATE trial showed that, among RA patients who had
previously discontinued TNF inhibitors 50% achieved
ACR20, 28.8% ACR50, and 12.4% ACR70 responses [36].
The ACR improvement and DAS remission criteria include
an acute-phase reactant component, so that there was con-
cern that the eﬀect of tocilizumab evaluated with these cri-
teria might be overestimated. However, it was found that,
even when criteria such as the Simpliﬁed Disease Activity
Index (SDAI) and Clinical Disease Activity Index (CDAI)
were used, remission rates for patients treated with toci-
lizumab were in the same range as those for patients treated
with TNF inhibitors [42, 43].
2.3.EﬃcacyofTocilizumabinActualMedicalPractice. Onthe
basis of the excellent results obtained for the eﬃcacy of
tocilizumab, it was approved in April 2008 for the treatment
of RA in Japan. The recommended posology of tocilizumab
(proprietary name, Actemra) is 8mg/kg, every 4 weeks. Sub-
sequently, the European Medicines Agency approved toci-
lizumab (proprietary name, RoACTEMRA) for RA in Jan-
uary 2009 at a recommended dose of 8mg/kg. In the United
States, it was approved for RA in January 2010, but the rec-
ommended starting dose is 4mg/kg administered once every
4 weeks followed by an increase to 8mg/kg depending on
clinical response. While the dosage diﬀers among countries,
tocilizumab has now been approved for the treatment of RA
in more than 90 countries worldwide [14].
In addition to clinical trials, the eﬃcacy of tocilizumab
was reconﬁrmed in actual medical practice. The ﬁnding by
thethreerecentstudies,theGermanphaseIIIbreal-lifestudy
(TAMARA study) [44, 45], the Danish nationwide cohorts
of RA patients (DANBIO registry) study [46], and the
multicenter retrospective real-life study (REACTION study)
[47, 48] are shown in Table 2. In the TAMARA study, 286
patients were registered for an analysis of the eﬀectiveness
and safety [44, 45], 41.6% of whom had previously been
treated with TNF inhibitors. ACR50 and ACR70 response
rates at week 24 were 50.7% and 33.9%, respectively,
while 47.6% of the patients achieved DAS remission and
54.9% the European League Against Rheumatism (EULAR)
good response. Remission rates with the new ACR/EULAR
Boolean-based criteria for clinical studies were 15.0% after
12 weeks and 20.3% after 24 weeks, and CDAI and SDAI
remission rates were 24.1% and 25.2%, respectively. For
the DANBIO registry in Denmark, 178 patients with RA
treated with tocilizumab were identiﬁed [46]. The disease
activity decreased at all-time points, with remission rates for
tocilizumab treatment of 39% after 24 weeks and 58% after
48weeks.EULARgoodormoderateresponserateswere88%
and 84%, respectively. These response rates were comparable
to those found for patients switching to their second TNF
inhibitors and to the response rates previously observed in
phase III clinical trials. In Japan, 229 patients were registered
in the REACTION study for an analysis of the eﬀectiveness
of tocilizumab [47, 48]. Clinical remission at week 52
was observed in 43.7% of the patients, radiographic non-
progression in 62.8%, and functional remission in 26.4%.
The retention rates at 24 and 52 weeks were 79.5% and
71.1%, respectively, and were the same for those with or
without previous anti-TNF treatment. These results indeed
show the eﬃcacy of tocilizumab for the treatment of RA in
actual medical practice.
2.4. Safety Proﬁle of Tocilizumab. The safety and tolerabil-
ity proﬁles of tocilizumab monotherapy for Japanese RA
patients obtained from six initial trials and ﬁve long-term
extensions have been published [49]. For these studies,
601 patients with a total exposure to tocilizumab of 2,188
patient-years (pt-yr) were enrolled. The medial treatment
duration was 3.8 years. The incidence of adverse eventsInternational Journal of Rheumatology 5
(AEs), including abnormal laboratory test ﬁndings, was
calculated as 465/100 pt-yr, with infections being the most
common serious AEs (6.2/100 pt-yr). Of the patients treated
more than 5 years, 59.7% met the DAS28 remission criteria
at 5 years, which demonstrates the excellent tolerability
and high eﬃcacy of tocilizumab. In addition, a systemic
literature review to assess the risk of AEs for RA patients
treated with tocilizumab reported that pooled odds ratios
(ORs) indicated statistical signiﬁcance for an increased risk
of AEs for patients treated with 8mg/kg of tocilizumab plus
methotrexate compared with controls (OR = 1.53; 95%CI =
1.26–1.86), as well as a heightened risk of infection (OR =
1.30; 95%CI = 1.07–1.58) [50]. However, no increases in the
incidence of malignancy or hepatitis were detected.
The results of an interim analysis of a postmarketing
surveillance of all patients treated with tocilizumab in Japan
were recently reported [51]. This analysis comprised 3,881
patients who received 8mg/kg of tocilizumab every 4 weeks,
and was observed for 28 weeks. Occurrence of a total
of 3,004 AEs in 1,641 patients (167/100pt-yr) and 490
serious AEs in 361 patients (27/100pt-yr) was reported.
The most frequent AE and serious AE were infection at
31/100pt-yr and 9/100pt-yr, respectively, with the majority
of infections being pneumonia and cellulitis. Cardiovascular
events were observed in 0.9% (myocardial infarction in 4
patients or 0.1%). Abnormalities in laboratory test ﬁndings,
such as increases in lipid and liver function parameters
were common, and total and serious AEs associated with
laboratorytestabnormalitieswere35/100pt-yrand2/100pt-
yr, respectively. The increased lipid level resulting from
tocilizumab administration is perhaps mediated by its eﬀect-
ing on lipoprotein receptor expression, since it was recently
shown that overproduction of IL-6 reduces blood lipid levels
via upregulation of very-low-density lipoprotein receptors
[52]. In contrast, we and others observed that HbA1c levels
and insulin sensitivity improved as a result of tocilizumab
treatment [53, 54]. While white blood cell and neutrophil
counts usually decreased just after tocilizumab injection, this
was not related to the incidence of infection. Twenty-ﬁve
patientsdiedforastandardizedmortalityratioof1.66,which
wassimilartotheresultsreportedforaJapanesecohortstudy
of RA. The results of this analysis thus demonstrated that
tocilizumab is acceptable in the actual clinical setting.
Seven cases of gastrointestinal (GI) perforation in six
patients were reported in this postmarketing surveillance.
In the worldwide Roche clinical trials, 26 (0.65%) cases of
GI perforation were found among patients with RA treated
with tocilizumab for a rate of 1.9/1,000pt-yr and most cases
appeared to be complications of diverticulitis [55]. This
rate is intermediate between the rates of GI perforations
of 3.9/1,000pt-yr for corticosteroids and 1.3/1,000pt-yr
for anti-TNFα agents reported in the United Health Care
database.
The reactivation of tuberculosis is a major concern
during anti-TNF treatment [56], but there is no medical
consensus regarding the eﬀe c to fI L - 6b l o c k a d eo nt u b e r c u -
losis. Okada et al. examined the eﬀects of IL-6 and TNFα
blockade on the development of tuberculosis infection in
mice and observed that there was less tuberculosis infection
for anti-IL-6R Ab than for anti-TNFα Ab [57]. In addition,
we showed that tuberculosis antigens-induced interferon
(IFN)-γ production was suppressed by the addition of
TNF inhibitors (inﬂiximab and etanercept) but not of
tocilizumab [58]. Although it seems likely that the incidence
of reactivation of tuberculosis is lower during tocilizumab
treatment than that during anti-TNF treatment, further
detailed studies will be needed to clarify this point.
2.5. The Place of Tocilizumab in Rheumatoid Arthritis Treat-
ment. A number of biologics are available for the treat-
ment of RA. These include anti-TNF blockers (inﬂiximab,
etanercept, adalimumab, golimumab, and certolizumab), an
IL-1 antagonist (anakinra), a B-cell depletor (rituximab),
an IL-6 receptor inhibitor (tocilizumab), and a T-cell
activation blocker (abatacept). These biological modiﬁers
target diﬀerent molecules and B cells, leading to diﬀerent
clinical eﬀects and causing diﬀerent adverse eﬀects. Since
no head-to-head comparative studies have been made of
the eﬃcacy of these various agents, it has not yet been
determined which of these biologics should be selected for
a given patient. Currently, one of the anti-TNF drugs is
chosen as a ﬁrst-line biologic, but between 14 and 38% of
patients show no or little response to anti-TNF treatment,
with as many as 40% of patients discontinuing these drugs
within a year and 50% within 2 years. The ﬁndings of the
RADIATE trial showed that RA patients who had previously
discontinued TNF inhibitors, mainly due to their ineﬃcacy,
achieved ACR20/50/70 responses of 50%, 28.8%, and 12.4%,
respectively, when tocilizumab was administered at 8mg/kg
every four weeks [36]. At present, tocilizumab is likely to be
prescribed as a second-line biologic therapy but will have to
overcomesigniﬁcantcompetition fromestablished anti-TNF
therapies.
Itisanticipatedthattocilizumabwillbeselectedasaﬁrst-
line biologic for moderately to severely active RA patients
with certain complications. AA amyloidosis is a serious
complication of RA, and amyloid ﬁbril deposition causes
progressive deterioration in various organs [59, 60]. Since
the gene activation of serum amyloid A, a precursor protein
of amyloid A ﬁbril, depends primarily on IL-6 [61, 62],
tocilizumab administration was found to promptly reduce
serum concentrations of SAA, just as in the case of CRP [60].
Three case reports showed the clinical ameliorative eﬀect of
tocilizumab on gastrointestinal symptoms due to intestinal
amyloidosis [63–65], and amyloid A ﬁbril deposits were
found to have disappeared in two cases after three injections
of tocilizumab [63, 65]. This suggests that tocilizumab may
be suitable as a ﬁrst-line drug for RA patients who are
complicated with or are at high risk of developing AA
amyloidosis.
2.6. Drug-Free Remission Rate. Remission induction is the
current goal for RA, and with the development of biological
modiﬁers, a growing number of RA patients has been able to
achieve this goal [66]. The long-term eﬃcacy after cessation
of tocilizumab followed by DAS28 remission was demon-
strated in the DREAM (drug-free remission after cessation
of actemra monotherapy) study [67]. The continuous rate6 International Journal of Rheumatology
of tocilizumab-free eﬃcacy was 35.1% at 24 weeks and
13.4% at 52 weeks. Serum levels of IL-6 and MMP-3 are
useful markers for identifying patients who may be able
to discontinue tocilizumab without risk of recurrence. In
addition, the RESTORE study (retreatment eﬃcacy and
safety to tocilizumab in patients with rheumatoid arthritis
at recurrence) demonstrated that retreatment of all relapsed
patients with tocilizumab resulted in re-remission [68].
3. Therapeutic Implicationsof Tocilizumab
for Other Systemic Autoimmune Diseases
3.1. Systemic Lupus Erythematosus. Systemic lupus erythe-
matosus (SLE) is a multisystem autoimmune disorder with
a broad spectrum of clinical presentations of unknown etiol-
ogy that mainly aﬀects young women [69]. The pathogenesis
of SLE remains unclear, but the concept of apoptosis goes
some way towards explaining how the immune system may
recognize mainly intracellular antigens. Defects in the clear-
ance of apoptotic cells have been recognized in SLE patients,
leading to aberrant uptake by macrophages, which then
present intracellular antigens to T and B cells, thus driving
the autoimmune process [70]. Cytokine dysregulation is
pervasive,anditsexpressionproﬁlesmayserveasamarkerof
diseaseactivityandseverity.Recentﬁndingshavehighlighted
type I interferon pathway [71]o rT h 1 7c e l la c t i v a t i o n[ 72]i n
the pathogenesis of SLE.
Levels of CRP have been shown to rise in acute illness
but not in SLE ﬂares, indicating that IL-6, a major regulator
of CRP production, has a minor role in SLE development.
However,recentﬁndingssuggestthatCRPdysregulationalso
plays a part in the pathogenesis of SLE [73]a n dS L Em a y
w e l lb eap o t e n t i a lt a r g e tf o rI L - 6b l o c k a d e[ 74]. Serum
IL-6 levels of SLE patients were elevated [75–77]. Urinary
excretion and renal expression of IL-6 was elevated in SLE
patients with active proliferating lupus nephritis [76, 78–81],
as were IL-6 levels in the cerebrospinal ﬂuid of SLE patients
with central nervous system involvement [82]. Compared
to healthy controls, SLE patients had signiﬁcantly more IL-
6 secreting peripheral blood mononuclear cells [83, 84].
Lymphoblastoid cells isolated from SLE patients produced
higher levels of IL-6 and blocking of IL-6 inhibited anti-
double-stranded DNA (dsDNA) Ab production in vitro
[85, 86], indicating that IL-6 is involved in autoantibody
production. In murine SLE models, age-associated increases
in serum IL-6, soluble IL-6R, and abnormal expression of
IL-6R have been detected in MRL/lpr mice [87–89]. In
old NZB/W mice, anti-IL-6 Ab reduced and exogenous
IL-6 increased production of IgG dsDNA Ab by B cells
[90, 91]. Furthermore, IL-6 administration exacerbated
glomerulonephritis [92, 93], while IL-6 blockade by means
of anti-IL-6R or anti-IL-6 Ab prevented the onset and
progression of the disease [94, 95]. Mice with epidermal loss
of JunB reportedly developed an SLE phenotype linked to
increased epidermal IL-6 secretion, and facial skin biopsies
of SLE patients displayed low levels of JunB protein expres-
sion, high IL-6, and activated STAT3 levels within lupus
lesions [96]. These ﬁndings led to an open-label phase I
dosage-escalation study of tocilizumab (2mg/kg, 4mg/kg or
8mg/kg, every 2 weeks for 12 weeks) with an enrollment of
16 SLE patients with mild-to-moderate disease activity [97].
Signiﬁcant improvement in the modiﬁed Safety of Estrogens
in Lupus Erythematosus National Assessment version of the
Systemic Lupus Erythematosus Disease Activity Index score
was observed in 8 of the 15 evaluable patients, accompanied
by a median reduction in anti-dsDNA Ab levels of 47%. The
percentage of CD38highCD19lowIgDnegative plasma cells in the
peripheral blood, which was higher for SLE patients than for
normal controls (mean 5.3% versus 1.2%), was signiﬁcantly
reduced to 3.1% at 6 weeks. These results indicate that
tocilizumab represents a promising therapeutic biologic for
SLE.
3.2.SystemicSclerosis. Systemicsclerosis(SSc)isaconnective
tissue disease, characterized by ﬁbrosis of the skin and
internal organs, vasculopathy, and immune abnormalities
[98]. IL-6 is a deﬁnite therapeutic target in SSc [99]. IL-
6 in the serum of SSc patients was reportedly elevated
and the level correlated with the skin severity score [100–
104]. Moreover, the culture supernatants of peripheral blood
mononuclear cells and skin tissues from SSc patients con-
tained higher concentrations of IL-6 than those from con-
trols [105–109]. In vitro studies demonstrated that IL-6 may
contribute to ﬁbrosis by inducing collagen production [110]
and induce α-smooth muscle actin (α-SMA) expression by
dermal ﬁbroblasts [111], leading to their diﬀerentiation into
myoﬁbroblasts. On the other hand, anti-IL-6 Ab suppressed
procollagen type 1 production in ﬁbroblasts derived from
SSc patients in vitro [112]. SSc serum mediated largely by
IL-6 was found to induce endothelial cell activation and
apoptosis in endothelial cell-neutrophil cocultures [113]. IL-
6isalsoassociatedwithhumoralandcellularimmunological
abnormalities in SSc [98, 99]. IL-6 is thus thought to play
a signiﬁcant role in producing the characteristics of SSc.
Moreover, in a SSc model mouse, induced by immunization
withtopoisomeraseIandcompleteFreund’sadjuvant,lossof
IL-6expressioncouldameliorateskinandlungﬁbrosis[114].
We also examined the clinical eﬀect of tocilizumab on two
diﬀuse SSc patients who had been resistant to conventional
treatment regimens [115]. Six months after the treatment,
both patients showed softening of the skin with reductions
of 50.7% and 55.7% for the total z-score determined with
the Vesmeter, a novel device for measuring the physical
properties of the skin [116], and of 51.9% and 23% for the
modiﬁed Rodnan total skin score. Histological examination
showed thinning of the collagen ﬁber bundles and reduction
of the number of α-SMA positive cells in the dermis. Since
there are few therapeutic drugs for SSc at the present time
[117], these improvements suggest that tocilizumab appears
to be a promising biologic for the treatment of SSc.
3.3. Polymyositis. The inﬂammatory myopathies encompass
a group of heterogenous muscle diseases which share
thecommonclinicalfeaturesofslowlyprogressivesymmetri-
cal muscle weakness, decreased muscle endurance, andInternational Journal of Rheumatology 7
fatigue [118]. They include polymyositis (PM), dermato-
myositis, and inclusion body myositis, but are generally
considered to be distinct diseases with diﬀerent pathophys-
iological mechanisms. Muscles produce IL-6 [119], and IL-
6 has been also shown to play a regulatory role in muscle
wasting [120]. Among these inﬂammatory myopathies, PM
appears to be another suitable target disease for tocilizumab.
Excessive IL-6 expression has been found in the sera and
inﬁltrating mononuclear cells in the muscles of PM patients
[121–123]. Inﬁltrating cytotoxic T cells are thought to be
involved in muscle ﬁber damage, and IL-6 functions as a
helper factor in the induction of cytotoxic T cells [124].
Moreover, in a model of myosin-induced experimental
myositis it was shown that control mice developed clini-
cally manifest muscle damage, whereas IL-6-deﬁcient mice
showed no clinical or histological signs of muscle damage
[125].InanothermodelofPM,knownasC-protein-induced
myositis, intraperitoneal administration of anti-IL-6R Ab
suppressed the severity of myositis preventatively as well as
therapeutically[126].Wetestedtheeﬃcacyoftocilizumabin
two PM patients who had been refractory to corticosteroids
and immunosuppressive drugs [127]. Creatine phosphok-
inase levels of both patients normalized and MR images
showed the disappearance of high-intensity zones in the
thigh muscles. These ﬁndings suggest that tocilizumab may
also be eﬀective as a novel drug for refractory PM.
Dermatomyositis is a complement-mediated microan-
giopathy associated with destruction of capillaries, hypoper-
fusion,andinﬂammatorystressontheperifascicularregions,
so that the pathology is diﬀerent from that of PM [118].
Production of IL-6 and type I interferon signature genes
was recently proposed as a biomarker for disease activity
in childhood dermatomyositis [128] ,w h i c ht h u sm a yb e
another disorder suitable for tocilizumab targeting.
3.4. Takayasu’s Arteritis and Giant Cell Arteritis. Vasculitis
refers to inﬂammation where blood vessels are the primary
site of inﬂammation. The pathological consequence of such
inﬂammation is destruction of the vessel wall, which is his-
tologically detected as ﬁbrinoid necrosis. Takayasu’s arteritis
(TA) and giant cell arteritis (GCA) belong to an entity
designated vasculitis syndrome, and involve both large and
medium-sized arteries [129, 130]. The pathogenesis of TA
and GCA remains unclear, but it is clear that IL-6 is involved
in their development [129–133]. Tocilizumab treatment for
a 20-year-old woman with refractory active TA improved
the clinical manifestations and abnormal laboratory ﬁndings
[134], and subsequent studies reported that tocilizumab
treatment induced a rapid remission in 2 patients with TA
and 5 patients with GCA [135]. Surprisingly, two of the
patients with GCA went into remission without concomitant
useofcorticosteroids.Moreover,tocilizumabwasalsoshown
to be eﬀective as rescue treatment for three GCA patients
for whom the prednisone dose could not be tapered to less
than 30mg/day [136]. Positron emission tomography/CT
scans revealed that in two patients generalized large-vessel
vasculitis was detected during the active phase, which
completely resolved upon a 6-month course of tocilizumab
therapy. These reports strongly imply that IL-6 inhibition
may serve as an innovative strategy for the treatment of both
TA and GCA. However, several studies have suggested that
GCA patients with a lesser inﬂammatory response without
an increase in IL-6 expression were at a higher risk of
developing ischemic manifestations than were other patients
[137], since the angiogenic activity of IL-6 oﬀers protection
against ischemia in such GCA patients [138]. These ﬁndings
indicate that further clinical studies are required to evaluate
the eﬃcacy and safety of tocilizumab for GCA and TA.
It is worthy of note that IL-6 has been also implicated
in the development of other types of vasculitis syndrome
such as polyarteritis nodosa (PAN) and antineutrophil-cyto-
plasmic-antibody- (ANCA) associated vasculitis [139–142].
However, so far there have been no reports about oﬀ-label
use of tocilizumab for PAN or ANCA-associated vasculitis.
4. Therapeutic Implications for Other
Autoimmune andInﬂammatory Diseases
On the basis of excellent results of the eﬃcacy of tocilizumab
for Castleman’s disease [143, 144] and systemic juvenile idio-
pathic arthritis [145–147] ,i th a sb e e na p p r o v e da n du s e da s
the ﬁrst-line biologic in Japan. Pilot studies and case reports
with oﬀ-label use of tocilizumab also indicate the potential
indications of this biologic for various other organ-speciﬁc
autoimmune and chronic inﬂammatory diseases. These
include relapsing polychondritis [148], acquired hemophilia
A[ 149], autoimmune hemolytic anemia [150], adult-onset
Still’s disease [151–165], Crohn’s disease [166], Bechet’s dis-
ease with posterior uveitis [167], polymyalgia rheumatica
[135, 168], remitting seronegative, symmetrical synovi-
tis with pitting edema [169], spondyloarthritides [170–
175], graft-versus-host disease [176, 177], TNF-receptor-
associated periodic syndrome [178], and pulmonary arterial
hypertension complicated with Castleman’s disease or mixed
connective tissue disease [179–181]. Further clinical trials
are essential, however, to evaluate the eﬃcacy and safety of
tocilizumab for these diseases.
5. Conclusion
Acute IL-6 synthesis provides a warning signal and protects
the host from environmental stress, while its prolonged
production causes the onset and progression of various
autoimmune diseases. Several clinical trials have veriﬁed the
eﬃcacy and safety of tocilizumab for RA, systemic juvenile
idiopathic arthritis and Castleman’s disease, resulting in
approvalofthisinnovativebiologicforthetreatmentofthese
diseases. Case reports of oﬀ-label use or pilot studies have
also raised the possibility that tocilizumab could become the
biological drug of choice for other systemic autoimmune
diseases including SLE, systemic sclerosis, polymyositis and
large vessel vasculitis. At present, the mechanisms through
which tocilizumab exerts its clinical ameliorative eﬀects
on phenotypically diﬀerent autoimmune diseases are not
completely understood. IL-6 blockade may suppress autoan-
tibody production or correct the imbalance of autoantigen-
speciﬁc Th17 and/or Th1 versus Treg. Thus, clariﬁcation of8 International Journal of Rheumatology
the mechanisms as well as further clinical trials to evaluate
the eﬃcacy and safety of tocilizumab for these diseases are
important issues.
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